

Acuity Target Safety Assessments (TSAs)

Knowledge is Power

Acuity TSAs are created by toxicologists, supported by artificial intelligence, to provide an understanding of target and modality safety liabilities and a risk mitigation plan.

Our Concise and Customised Acuity TSAs Will:

- Increase your knowledge of potential safety liabilities
- Support timely and informed decision making
- Maximise the use of your limited resources
- Boost confidence with a comprehensive search

acuity

Expert-driven - AI-enabled



“The target safety evaluation was perfect. Our toxicologist was very happy with the final document as was the project team. Not only was the document great, it was delivered on time and the turn-around time for the edits was outstanding.”

James Murray, Toxicologist,
Sanofi.

Acuity TSAs are authored by project toxicologists familiar with the project team environment and objectives

Meet Some of the Team



Professor Ruth Roberts

A co-founder of ApconiX, Professor Ruth Roberts has over 25 years of experience in leading drug safety. Ruth is also chair and Director of Drug Discovery at the University of Birmingham, UK and previously Global Head of Regulatory Safety at AstraZeneca.



Dr James Sidaway

Dr James Sidaway is an experienced and innovative toxicologist having worked for over 20 years in the pharmaceutical industry with AstraZeneca and as an independent consultant. As a molecular investigative toxicologist he helped resolve safety issues for a wide range of drug discovery and development projects across the major therapy areas.



Dr Claire Sadler

Dr Claire Sadler is an experienced project toxicologist and former Director of Discovery Safety within AstraZeneca. Claire specialises in early project safety assessment, identifying and mitigating risks from target identification through to early clinical trials.



Dr Karen Featherstone

Dr Karen Featherstone is a Medical Writer with extensive experience in communicating health economics and outcomes research (HEOR) through a range of market access materials. Having worked within a global contract research organisation, she has a track record of delivering high quality, evidence-based materials to clients from across the pharmaceutical industry.



Phumzile Sikakana

Phumzile Sikakana is an experienced target safety assessment specialist. Phum studied Biomedical Sciences at Cardiff University before completing her Master's degree at Sheffield University in 2018 where she received a distinction.

“Working with ApconiX was effortless! They have provided high quality target safety assessments with a focus on comprehensive interpretation of findings. The information provided has helped contribute to decisions on activities when moving early molecules forward.”

Meet Some More of the Team



Dr Duncan Armstrong

Dr Duncan Armstrong is an expert pharmacologist with an international reputation in secondary and safety pharmacology gained over 18 years in drug discovery and development at AstraZeneca and Novartis.



Dr Nicholas Coltman

Dr Nicholas Coltman recently completed his PhD in in vitro nonclinical toxicological research (hepatotoxicity, genotoxicity and advanced in vitro models) through a BBSRC iCASE Scholarship with Sygnature Discovery Ltd at the University of Birmingham. Nic has invaluable industry experience first at Envigo and then at Sygnature Discovery.



Dr Sean Hammond

Dr Sean Hammond holds a PhD in immunopharmacology from the University of Liverpool focused on developing experimental and conceptual means to address T-cell mediated hypersensitivity reactions. He has long-standing links with drug safety research at Liverpool where he received the Syngenta prize for pharmacology and where he maintains an academic profile.



Dr Helen Garside

Dr Helen Garside has over 10 years of experience in the pharmaceutical industry focused on predictive and mechanistic toxicology. She has expertise in early project toxicology gained through roles in discovery safety and safety pharmacology, supporting projects across multiple therapy areas.



Michelle Blissett

With almost 20 years devoted to preclinical toxicology, Michelle Blissett has developed an excellent ability to conduct extensive literature searches, interrogating, analysing and interpreting data and has contributed to regulatory and scientific reports and produced numerous literature reviews. As a Senior Toxicologist, Michelle has experience of clinical chemistry, haematology, cytogenetics and conducting preclinical studies for clients globally.



William Humfrey

Will Humfrey received an Integrated Master's degree in biomedical science at the University of Sheffield where he gained an understanding of human health, disease processes and developed both practical and written skills. Particularly enjoying literature searches, critical reviews, data analysis and report writing, Will is a recent addition to our target safety assessment team.

At least 50% of drug safety failures are attributable to target related effects



Understand Potential Liabilities Early and Facilitate Informed Decision Making

What Is a Target Safety Assessment?

A TSA brings together public domain information (target homology, gene and protein expression profiles, transgenic and mutation phenotype data) with the expertise of experienced toxicologists into a concise report that identifies key risks by organ/tissue.

Why Are TSAs Important in Drug Discovery and Development?

Understanding potential safety liabilities associated with a target at an early point in a project helps you to anticipate and manage issues before they arise. An Acuity TSA forms the basis of a risk mitigation plan including the ranking of risks and potential next steps.

What Can Be Included in an Acuity TSA?

- Executive summary
- Homology, expression, transgenic and mutation phenotypes
- Key risks identified and categorised by tissue
- Competitor information (public domain)
- Mitigation plans with ranking of risks and potential next steps
- PowerPoint ready for presentation